|
Name |
mollicellin N
|
Molecular Formula | C21H18O8 | |
IUPAC Name* |
8,13-dihydroxy-2,2,5,10-tetramethyl-4,11-dioxo-3H-chromeno[6,7-b][1,4]benzodioxepine-7-carbaldehyde
|
|
SMILES |
CC1=CC(=C(C2=C1C(=O)OC3=C(O2)C(=C4C(=O)CC(OC4=C3O)(C)C)C)C=O)O
|
|
InChI |
InChI=1S/C21H18O8/c1-8-5-11(23)10(7-22)17-13(8)20(26)28-19-15(25)18-14(9(2)16(19)27-17)12(24)6-21(3,4)29-18/h5,7,23,25H,6H2,1-4H3
|
|
InChIKey |
FMZRBSGCMFABIX-UHFFFAOYSA-N
|
|
Synonyms |
mollicellin N; 0U2A24WM0U; CHEBI:68727; 1179374-69-6; 2H,11H-1-Benzopyrano(6,7-b)(1,4)benzodioxepin-7-carboxaldehyde, 3,4-dihydro-8,13-dihydroxy-2,2,5,10-tetramethyl-4,11-dioxo-; UNII-0U2A24WM0U; Mollicelline N; CHEMBL1080425; DTXSID101104832; Q27137147; 3,4-Dihydro-8,13-dihydroxy-2,2,5,10-tetramethyl-4,11-dioxo-2H,11H-1-benzopyrano[6,7-b][1,4]benzodioxepin-7-carboxaldehyde; 8,13-dihydroxy-2,2,5,10-tetramethyl-4,11-dioxo-3,4-dihydro-2H,11H-chromeno[6,7-b][1,4]benzodioxepine-7-carbaldehyde
|
|
CAS | 1179374-69-6 | |
PubChem CID | 44254336 | |
ChEMBL ID | CHEMBL1080425 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 398.4 | ALogp: | 3.0 |
HBD: | 2 | HBA: | 8 |
Rotatable Bonds: | 1 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 119.0 | Aromatic Rings: | 4 |
Heavy Atoms: | 29 | QED Weighted: | 0.414 |
Caco-2 Permeability: | -4.954 | MDCK Permeability: | 0.00002120 |
Pgp-inhibitor: | 0.051 | Pgp-substrate: | 0 |
Human Intestinal Absorption (HIA): | 0.511 | 20% Bioavailability (F20%): | 0.007 |
30% Bioavailability (F30%): | 0 |
Blood-Brain-Barrier Penetration (BBB): | 0.011 | Plasma Protein Binding (PPB): | 97.08% |
Volume Distribution (VD): | 0.742 | Fu: | 1.69% |
CYP1A2-inhibitor: | 0.512 | CYP1A2-substrate: | 0.125 |
CYP2C19-inhibitor: | 0.365 | CYP2C19-substrate: | 0.099 |
CYP2C9-inhibitor: | 0.785 | CYP2C9-substrate: | 0.772 |
CYP2D6-inhibitor: | 0.006 | CYP2D6-substrate: | 0.186 |
CYP3A4-inhibitor: | 0.286 | CYP3A4-substrate: | 0.152 |
Clearance (CL): | 1.131 | Half-life (T1/2): | 0.279 |
hERG Blockers: | 0.001 | Human Hepatotoxicity (H-HT): | 0.027 |
Drug-inuced Liver Injury (DILI): | 0.501 | AMES Toxicity: | 0.113 |
Rat Oral Acute Toxicity: | 0.998 | Maximum Recommended Daily Dose: | 0.912 |
Skin Sensitization: | 0.576 | Carcinogencity: | 0.061 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.885 |
Respiratory Toxicity: | 0.638 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC000920 | 0.775 | D06XZW | 0.233 | ||||
ENC000919 | 0.730 | D0FX2Q | 0.227 | ||||
ENC002864 | 0.674 | D0WY9N | 0.212 | ||||
ENC002621 | 0.625 | D0G3DL | 0.209 | ||||
ENC002677 | 0.591 | D0Q0PR | 0.209 | ||||
ENC005960 | 0.564 | D01XWG | 0.207 | ||||
ENC000631 | 0.564 | D0R6RC | 0.206 | ||||
ENC004156 | 0.535 | D03RTK | 0.205 | ||||
ENC002865 | 0.525 | D08LTU | 0.204 | ||||
ENC005959 | 0.500 | D04ITO | 0.202 |